NDA 209410 · Supernus Pharms
Osmolex Er
Amantadine Hydrochloride · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Feb 16, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
324
86 Phase 3, 21 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- OSMOLEX ER · AMANTADINE HYDROCHLORIDE EQ 161MG BASE · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OSMOLEX ER · AMANTADINE HYDROCHLORIDE EQ 193MG BASE · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OSMOLEX ER · AMANTADINE HYDROCHLORIDE EQ 258MG BASE · TABLET, EXTENDED RELEASE, ORAL · Discontinued
- OSMOLEX ER · AMANTADINE HYDROCHLORIDE EQ 129MG BASE · TABLET, EXTENDED RELEASE, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Amantadine" as an intervention, any sponsor and status, largest first.
- Safety and Efficacy Evaluation of S (+) - Ketamine in AdultsPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04837170 · 12,000 participants (planned) · Start May 1, 2021 · Primary completion Jun 1, 2022
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: Postoperative Pain; Adults; Anesthesia
- Safety and Efficacy Evaluation of S (+) - Ketamine in ChildrenPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04834427 · 3,000 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 1, 2024
Drug: Conventional therapy + S (+)-Ketamine; Conventional therapy · For: S-ketamine; Esketamine; Acute Pain and 6 more
Sites: Beijing, China
- Pragmatic Trial of Obsessive-compulsive DisorderPivotal-lookingRecruiting
Shanghai Mental Health CenterAcademic, hospital or other
NCT04539951 · 1,600 participants (planned) · Start Sep 22, 2020 · Primary completion Jun 30, 2027
Drug: Sertraline 200 milligram(mg); Sertraline 300 milligram(mg) and 4 more · For: Obsessive-Compulsive Disorder
Sites: Shanghai, China
- Memantine in Patients With Chronic GlaucomaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00168350 · 1,179 participants · Start Mar 2000 · Primary completion Sep 2006
Drug: memantine · For: Open-Angle Glaucoma
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised TrialPivotal-lookingRecruiting
University of EdinburghAcademic, hospital or other
NCT04302870 · 1,150 participants (planned) · Start Feb 27, 2020 · Primary completion Dec 2030
Drug: Memantine Hydrochloride Oral Solution; Trazodone Hydrochloride oral solution and 4 more · For: Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Sites: Portadown, United Kingdom; Aberdeen, United Kingdom; Birmingham, United Kingdom · 22 sites in all
- Memantine in Patients With Chronic GlaucomaPivotal-lookingCompleted
AllerganAbbVie (ABBV)
NCT00141882 · 1,119 participants · Start Mar 1999 · Primary completion Jan 2006
Drug: memantine · For: Open-Angle Glaucoma
Forest LaboratoriesAbbVie (ABBV)
NCT01592786 · 906 participants · Start Jun 2012 · Primary completion Jul 2013
Drug: Memantine Hydrochloride (HCl) · For: Autism Spectrum Disorder (ASD); Autism; Autistic Disorder and 4 more
Sites: Dothan, Alabama; Phoenix, Arizona; Tucson, Arizona · 118 sites in all
- Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for ComplicationsPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01227967 · 881 participants · Start Sep 2010 · Primary completion May 2, 2016
Drug: Amantadine, Ribavirin, Oseltamivir; Oseltamivir · For: Influenza
Sites: Birmingham, Alabama; Chandler, Arizona; Glendale, Arizona · 91 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Osmolex ER (Amantadine HCl)
2024 spending
$328K
Beneficiaries
155
286 claims
Per beneficiary
$2,117
$19.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $560,068 |
| 2021 | $1,201,180 |
| 2022 | $1,939,240 |
| 2023 | $2,041,525 |
| 2024 | $328,102 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antiviral Medications for Treatment of Nonsevere Influenza: A Systematic Review and Network Meta-Analysis.
Gao Y, Zhao Y, Liu M, et al. · JAMA Intern Med 2025 · Network Meta-Analysis, Systematic Review
- Pharmacological Treatment of Agitation and/or Aggression in Patients With Traumatic Brain Injury: A Systematic Review of Reviews.
Rahmani E, Lemelle TM, Samarbafzadeh E, et al. · J Head Trauma Rehabil 2021 · Systematic Review
- Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
Zhao Y, Gao Y, Guyatt G, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Influenza.
Jefferson T · BMJ Clin Evid 2009 · Systematic Review
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Multiple sclerosis.
Nicholas R, Chataway J · BMJ Clin Evid 2009 · Systematic Review
Sponsor: Supernus Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.